PUBLISHER: The Business Research Company | PRODUCT CODE: 1751070
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751070
Personalized medicine biomarkers are specific biological indicators that customize medical treatments for individual patients based on their unique genetic, molecular, or physiological characteristics. These biomarkers help predict how a patient will respond to a particular drug, allowing healthcare providers to select the most effective and safest treatment options.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of biomarkers in personalized medicine include genomic, proteomic, metabolic, and other types. Genomic biomarkers refer to specific genes or genetic mutations that provide insights into how diseases develop and progress in individuals. These biomarkers are used for a variety of disease indications, such as oncology, neurology, diabetes, autoimmune diseases, cardiology, and more. They serve various purposes, including early detection or screening, diagnosis, treatment selection, and monitoring. Personalized medicine biomarkers are utilized by a range of end users, including hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others.
The personalized medicine biomarkers market research report is one of a series of new reports from The Business Research Company that provides personalized medicine biomarkers market statistics, including personalized medicine biomarkers industry global market size, regional shares, competitors with a personalized medicine biomarkers market share, detailed personalized medicine biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine biomarkers industry. This personalized medicine biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The personalized medicine biomarkers market size has grown rapidly in recent years. It will grow from $22.85 billion in 2024 to $26.98 billion in 2025 at a compound annual growth rate (CAGR) of 18.0%. The growth during the historic period can be attributed to the increasing prevalence of chronic diseases, the rising adoption of companion diagnostics, growing investment in biomarker research, a heightened focus on early diagnosis and preventive healthcare, and regulatory support for biomarker-based therapies.
The personalized medicine biomarkers market size is expected to see rapid growth in the next few years. It will grow to $51.53 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth during the forecast period can be attributed to the expanding applications of biomarkers in precision oncology, rising demand for targeted therapies, a growing focus on early disease detection, increasing consumer demand for personalized approaches, and supportive government policies and funding. Key trends expected in the forecast period include the adoption of a multi-omics approach for biomarker identification, the development of liquid biopsy-based biomarkers, a growing use of digital biomarkers, the integration of AI and machine learning in biomarker discovery, and the expansion of real-world evidence in biomarker validation.
The growing prevalence of chronic diseases is expected to drive substantial growth in the personalized medicine biomarkers market. Chronic diseases are long-term conditions that develop gradually and persist for extended periods, often requiring ongoing medical care or affecting daily activities. The rise in chronic diseases is largely attributed to unhealthy lifestyle choices, poor diets, insufficient physical activity, and high stress levels. Personalized medicine biomarkers play a key role in managing these conditions by tailoring treatments based on individual genetic and molecular profiles. These biomarkers help identify the most effective therapies, predict disease progression, and minimize adverse effects. For example, the World Health Organization (WHO) predicts that by 2050, the number of new cancer cases will exceed 35 million, a 77% increase from 2022. This escalating prevalence of chronic diseases is accelerating demand for personalized medicine biomarkers.
Companies in the personalized medicine biomarkers market are focusing on obtaining regulatory approvals to enhance product credibility, expand their market reach, and improve patient outcomes. Regulatory approvals are essential as they ensure that medical products, treatments, or technologies meet safety, efficacy, and quality standards. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received FDA approval for its cancer biomarker test and two companion diagnostics. The test uses next-generation sequencing (NGS) technology to identify genetic mutations in cancer cells, allowing clinicians to select the most appropriate treatments based on individual biomarkers. This approval represents a significant milestone in precision oncology, improving the speed and accuracy of treatment selection and enhancing personalized care for cancer patients.
In February 2025, Renovaro Inc., a US-based biotechnology firm, merged with BioSymetrics Inc. to boost AI-driven biomarker discovery and precision medicine initiatives. The merger is set to enhance drug development and facilitate the creation of personalized treatment strategies, particularly for complex diseases. BioSymetrics Inc., a Canada-based company specializing in phenomics-driven drug discovery, uses machine learning to integrate clinical and experimental data, advancing the field of precision medicine.
Major players in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.
North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in personalized medicine biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the personalized medicine biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The personalized medicine biomarkers market consists of sales of biomarker-based diagnostic kits, reagents, testing platforms, epigenetic biomarkers, companion diagnostics, predictive biomarkers, prognostic biomarkers, and multi-omics biomarkers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Personalized Medicine Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on personalized medicine biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for personalized medicine biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The personalized medicine biomarkers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.